The High Flux Reactor (HFR) in Petten, Noord-Holland, produces two thirds of the medical isotopes in Europe, but it reaches its useful life around 2030. The PALLAS-reactor is therefore needed to maintain the nuclear infrastructure in Petten, the Netherlands.
The use of nuclear medicine is booming, especially for new therapies. Around 200,000 patient treatments with therapeutic isotopes take place in Europe every year. This number is expected to increase by 8 per cent annually.